Evaluating the implementation of the RACE-instrument in asthma and COPD patients with inhaled maintenance therapy

• Conditions: Asthma and COPD

• Registration Number: NL-OMON29180
• Lead Sponsor: This study is supported by AstraZeneca and the Royal Dutch Pharmacists Association (KNMP) with an unconditional research grant.

Brief Summary

The data obtained in this trial will be disclosed as an international publication.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 400

Inclusion Criteria

= 18 years of age
- Being treated for asthma with ICS maintenance therapy or
- Being treated for COPD with LAMA or LABA
according to dispensing data for these conditions present in the pharmacy information systems.
- Able to answer to online questionnaires

Exclusion Criteria

- Concomitant asthma and COPD, suspicions hereof or diagnosed with other significant lung
diseases from information present in the pharmacy
- Incapability to speak, write and comprehend the Dutch language
- Presence of any cognitive impairments

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary objective is to evaluate the feasibility and acceptability of the RACE-instrument with complex multidimensional interventions provided in consultations by community pharmacists in asthma and COPD patients with maintenance inhaler therapy.

Secondary Outcome Measures

Name	Time	Method
As secondary objective the effectiveness of personal support and tailored care provided with the RACE-instrument and its complex multidimensional interventions by community pharmacists is compared between IG and CG patients regarding number of barriers to self-management with inhaled maintenance therapy, the achievement of personal goals and disease stability.